Selected Stock Price Target News of the Day — June 9, 2026

The stock price target news moving markets on Tuesday, June 9 spans three companies in completely different businesses. Oracle is the headline, with four analysts raising targets ahead of a Q4 earnings report due Wednesday. Apple is getting a fresh look from Morgan Stanley as its annual developer conference draws closer. And Nurix Therapeutics is still drawing analyst attention two trading days after a Roche partnership sent shares up 43%. Each story has a different driver. Each one says something about where institutional money is looking right now.

Oracle Stock Price Target News: Four Analysts, One Morning

Oracle ($ORCL) reports Q4 fiscal 2026 earnings on Wednesday, June 10. That’s tomorrow. And this morning, four analysts came out with raised price targets on the same stock within hours of each other.

B of A Securities analyst Bradley Sills lifted his ORCL target from $200 to $240, keeping a Buy rating. Sills carries a 72.92% price target met ratio documented across his calls at BAML. That puts him well above the average for sell-side technology coverage.

Evercore analyst Kirk Materne moved his target from $220 to $245, keeping an Outperform. Materne holds a 70.12% hit ratio across 523 documented price targets at Evercore. His coverage spans 30 stocks with a focus on enterprise software.

The largest single raise came from TD Cowen. Analyst Derrick Wood took his Oracle target from $250 to $300, maintaining a Buy. Wood has a 73.11% price target met ratio at TD Cowen, compiled across 834 calls on 31 technology stocks. His $300 target is the highest of the group.

Oppenheimer analyst Brian Schwartz also moved higher, pushing from $235 to $275 and staying at Outperform. Schwartz holds a 55.35% met ratio at Oppenheimer across 812 tracked price targets. A broad body of work that skews heavily bullish: 97% of his documented ratings sit at Buy.

What Analysts Are Watching in the Q4 Print

The common thread in all four raises is Oracle Cloud Infrastructure, or OCI. Oracle has been winning cloud contracts at a pace that surprised Wall Street through most of fiscal 2026. AI workload demand has driven a surge in new data center commitments. That’s what analysts are pricing in ahead of Wednesday’s report.

There’s also a timing factor. The fact that Sills, Materne, Wood, and Schwartz are all raising now suggests they expect the numbers to hold up.

Oracle’s stock has been one of the more consistent performers in large-cap tech over the past 18 months. Wednesday’s report will either validate this pre-earnings consensus or force a quick recalculation. Either way, the analyst positioning going into earnings is unusually unified.

Apple and Morgan Stanley’s WWDC Call: $330 to $360

Morgan Stanley analyst Erik Woodring raised his Apple price target from $330 to $360 this morning. The rating stays at Overweight. The timing is not random.

Woodring has been watching WWDC 2026 closely. Apple’s Worldwide Developers Conference is expected to reshape how investors think about the company’s AI positioning. Woodring’s research note frames it as a potential narrative shift. From Apple as a company “behind on AI” to Apple as an outright AI winner. He points to WWDC 2024 as the template. That year, a clear software AI roadmap drove 20-point outperformance in the stock.

Woodring carries a 79.44% price target met ratio at Morgan Stanley, built across 813 documented price targets on 29 stocks. That’s one of the stronger track records in consumer technology coverage on AnaChart.

What’s at Stake at WWDC

Apple’s position in the AI conversation has been complicated. The company has an installed base of over two billion active devices. Its privacy-first chip architecture gives it real advantages in on-device AI inference. But the public narrative has favored companies with cloud AI products and flashier developer toolkits.

WWDC is the moment Apple typically resets that story. Woodring’s bull case runs from $365 to $385, and as high as $440 in the most optimistic scenario. His base case at $360 reflects a more measured read: WWDC delivers, but doesn’t completely reshape the narrative overnight.

The $30 jump in his target is meaningful on a stock of Apple’s size. It implies that Woodring sees real upside from current levels if the conference delivers. He’s not guaranteeing it. But he’s making a public call ahead of the event, which is itself a signal worth noting.

Nurix Therapeutics: Roche Deal Keeps Analyst Interest Alive

Nurix Therapeutics announced a global collaboration with Roche on June 6. The deal covers bexobrutideg, an oral BTK degrader in development for B-cell cancers. Roche is paying $700 million upfront. Total potential value of the collaboration reaches $2.3 billion. U. S. profits are split 50/50, with Roche leading development outside the country and tiered royalties flowing back to Nurix.

The collaboration drew an immediate analyst response. That kind of move tends to flush out analysts who need to update their models. Two did so today.

Jefferies analyst Roger Song raised his NRIX target from $41 to $45, keeping a Buy rating. Song has a 38.06% price target met ratio at Jefferies across 194 documented calls, mostly in healthcare. Early-stage biotech is a category where met ratios run lower. Stocks either work or they don’t. The binary nature of clinical data makes straight hit-rate comparisons less meaningful than in large-cap coverage.

BTIG analyst Jeet Mukherjee also updated his view today. He raised the BTIG price target on NRIX from $30 to $32, maintaining a Buy. Mukherjee is not currently tracked in AnaChart’s database.

Reading the Gap Between the Two Targets

The two price targets tell a story on their own. Song at Jefferies lands at $45. Mukherjee at BTIG lands at $32. That’s a $13 gap on the same stock, the same day, after the same catalyst. It reflects genuine disagreement about how to value the Roche collaboration. The deal is closed. The stock has already moved 43%.

BTIG’s conservative raise might reflect the 43% move already baked into the price. Jefferies seems to be assigning more terminal value to the partnership and the pipeline it unlocks. Phase 3 trials for bexobrutideg are expected to start later this summer. That’s the next event that will force an update from both firms.

BTK degraders represent a next-generation approach in blood cancer treatment. Existing BTK inhibitors, drugs like ibrutinib and zanubrutinib, face resistance issues over time. A degrader works differently: it breaks down the BTK protein entirely rather than just blocking it. That’s the scientific rationale behind Roche’s interest and the $700 million bet on Nurix.

The stock enters Phase 3 with a major pharma partner now on board. That’s a very different risk profile than it had two weeks ago. Whether the current price fully reflects that shift is exactly what Song and Mukherjee disagree on.

The full price target history behind today’s calls is available on AnaChart. That includes Oracle, Apple, and Nurix Therapeutics, all covered through the analyst price target dataset. The dataset covers 661,383 documented price targets from 7,191 analysts. That’s 18 years of Wall Street calls, all searchable by analyst, broker, and ticker.